Biocartis Group NV said it signed a new agreement with AstraZeneca (AZN,AZN.L), aiming to provide access to rapid and easy-to-use Idylla EGFR testing products at selected hospital sites in Biocartis' European and global distributor markets1 to support the identification of patients with EGFR mutations.
The new agreement expands the existing master collaboration agreement between Biocartis and AstraZeneca, which was established to promote and bolster access to faster molecular diagnostic biomarker results.
Biocartis noted that the agreement also builds on the conclusion of the large prospective lung cancer FACILITATE study, co-sponsored by AstraZeneca and presented in September last year at the renowned ESMO Virtual Congress. The study concluded that Idylla EGFR testing may add value in a clinical setting to generate actionable EGFR mutation results for non-small cell lung cancer patients faster than routinely used methods.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.